title: Treatment of Kawasaki disease by different doses of immunoglobulin: a meta analysis of efficacy and safety.
abstract: OBJECTIVE
  To assess the efficacy and safety of different doses of immunoglobulin in the treatment of Kawasaki disease (KD).
  
  
  METHODS
  The papers related to the treatment of KD were electronically searched in the databases including PubMed, EMBASE, Cochrane Library, CNKI, VIP and Wanfang. Randomized clinical trials (RCT) on the treatment of KD with different doses of immunoglobulin were included and assessed for quality. A Mata analysis was performed by RevMan 5.0.
  
  
  RESULTS
  Twenty-eight RCTs involving 2,596 cases were included. The results of Meta analysis showed that there were no significant differences in the incidences of coronary artery injuries at various phases, adverse reactions, and fever disappearance time between the immunoglobulin treatment groups at the doses of 1 g/(kg•d) for 1-2 days or 2 g/(kg•d) for single use. The fever disappearance time in the immunoglobulin treatment group at the dose of 1 g/(kg•d) for 1-2 days was significantly shorter than that in the immunoglobulin treatment group at the dose of 400 mg/(kg•d) for 4-5 days, but there were no significant differences in the incidences of coronary artery injuries at the acute phase and 6 months after treatment and in the adverse effects between the two groups. The incidence of coronary artery injuries at the acute phase and 6 months after treatment was significantly lower and the fever disappearance time was significantly shorter in the immunoglobulin treatment group at the dose of 2 g/(kg•d) for single use than those in the immunoglobulin treatment group at the dose of 400 mg/(kg•d) for 4-5 days, but there were no significant differences in the incidences of coronary artery injuries at the subacute phase and 12 months after treatment and adverse effects between the two groups.
  
  
  CONCLUSIONS
  There are similar efficacy for KD between the immunoglobulin treatment groups at the doses of 1 g/(kg•d) for 1-2 days and 2 g/(kg•d) for single use. The fever disappearance time in the two groups is shorter than that in the treatment group at the dose of 400 mg/(kg•d) for 4-5 days.
authors.affiliation: Department of Pediatrics, First Clinical Medical College of Lanzhou University, Lanzhou 730000, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Pediatrics, First Clinical Medical College of Lanzhou University, Lanzhou 730000, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Ma
authors.affiliation: Department of Pediatrics, First Clinical Medical College of Lanzhou University, Lanzhou 730000, China.
authors.forename: Li-Xing
authors.initials: LX
authors.lastname: Lin
authors.affiliation: Department of Pediatrics, First Clinical Medical College of Lanzhou University, Lanzhou 730000, China.
authors.forename: Yi-Ming
authors.initials: YM
authors.lastname: Xue
keywords: Immunoglobulin; Kawasaki disease; child; meta analysis
references.citation: Rheumatol Int. 2010 Apr;30(6):841-6
references.pmid: 20049445
references.citation: Recent Pat Cardiovasc Drug Discov. 2008 Jun;3(2):141-4
references.pmid: 18537765
references.citation: Pediatr Int. 1999 Feb;41(1):1-7
references.pmid: 10200128
references.citation: J Korean Med Sci. 2008 Aug;23(4):718-22
references.pmid: 18756064
references.citation: Zhonghua Er Ke Za Zhi. 2006 Dec;44(12):891-5
references.pmid: 17254453
references.citation: Lancet. 2004 Aug 7-13;364(9433):533-44
references.pmid: 15302199
references.citation: Zhonghua Yi Xue Za Zhi. 2007 Nov 27;87(44):3119-21
references.pmid: 18269869
references.citation: Mod Rheumatol. 2004;14(5):361-6
references.pmid: 17143694
references.citation: Yonsei Med J. 2006 Dec 31;47(6):759-72
references.pmid: 17191303
references.citation: J Pediatr. 2002 Apr;140(4):450-5
references.pmid: 12006960
references.citation: Eur J Pediatr. 2007 Jun;166(6):565-71
references.pmid: 17103193
references.citation: N Engl J Med. 1991 Jun 6;324(23 ):1633-9
references.pmid: 1709446
references.citation: J Pediatr. 1993 Apr;122(4):538-42
references.pmid: 8463897
references.citation: Curr Opin Rheumatol. 2006 Jan;18(1):33-8
references.pmid: 16344617
references.citation: Arch Cardiol Mex. 2007 Oct-Dec;77(4):299-307
references.pmid: 18361075
references.citation: Circulation. 2004 Oct 26;110(17 ):2747-71
references.pmid: 15505111
references.citation: J Nippon Med Sch. 2004 Feb;71(1):51-6
references.pmid: 15129596
references.citation: Clin Pediatr (Phila). 2002 Oct;41(8):597-601
references.pmid: 12403377